Table 4 of
Daruich, Mol Vis 2019; 25:610-624. Table 4 of
Daruich, Mol Vis 2019; 25:610-624.
Table 4. Registered trials of the bile acids for neurodegenerations
| Status | Study title | ClinicalTrials.gov Identifier | Condition | Study design | Intervention |
|---|---|---|---|---|---|
| Completed | Ursodeoxycholic Acid for Rhegmatogenous Retinal Detachment | NCT02841306 | Rhegmatogenous Retinal Detachment | Phase 1 clinical trial Non-randomized Parallel Assignment Open labeled | UDCA 26 participants |
| Recruiting | Trial of Ursodeoxycholic Acid (UDCA) for Parkinson Disease: The “UP” Study | NCT03840005 | Parkinson Disease | Phase 2 clinical trial Placebo Controlled, Randomized Double Blind | UDCA 30 participants |
| Not yet recruiting | Brain Bioenergetics in Parkinson Disease and Response to Repeated Oral UDCA Treatment | NCT02967250 | Parkinson Disease | Phase 1 clinical trial Non-randomized Open labeled Single Group Assignment | UDCA 20 participants |
| Unknown status | Ursodiol in Huntington's Disease | NCT00514774 | Huntington Disease | Phase 1 clinical trial Randomized Parallel Assignment Double Blind | UDCA 21 participants |
| Recruiting | Safety and Efficacy of TUDCA as add-on Treatment in Patients Affected by Amyotrophic Lateral Sclerosis | NCT03800524 | Amyotrophic Lateral Sclerosis | Phase 3 clinical trial Placebo Controlled, Randomized Double Blind | TUDCA 440 participants |
| Recruiting | A Trial of Bile Acid Supplementation in Patients With Multiple Sclerosis | NCT03423121 | Progressive Multiple Sclerosis | Phase 1–2 clinical trial Placebo Controlled, Randomized Double Blind | TUDCA 60 participants |
| Recruiting | Study to Assess the Safety and Biologic Activity of AMX0035 for the Treatment of Alzheimer Disease | NCT03533257 | Alzheimer Disease | Phase 2 clinical trial Placebo Controlled, Randomized Double Blind | AMX0035 (TUDCA and Phenylbutyrate) 100 participants |
| Active, non- recruiting | AMX0035 in Patients With Amyotrophic Lateral Sclerosis | NCT03127514 | Amyotrophic Lateral Sclerosis | Phase 2 clinical trial Placebo Controlled, Randomized Double Blind | AMX0035 (TUDCA and Phenylbutyrate) 132 participants |
| Enrolling by invitation | Open Label Extension Study of AMX0035 in Patients With Amyotrophic Lateral Sclerosis | NCT03488524 | Amyotrophic Lateral Sclerosis | Phase 2 clinical trial Single Group Assignment Non-randomized Open label | AMX0035 (TUDCA and Phenylbutyrate) 132 participants |